Novo Nordisk A (NVO) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Novo Nordisk A  (NYSE: NVO)


Novo Nordisk A's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Novo Nordisk A's ROA in the first quarter of 2026?
Novo Nordisk A achieved a return on average assets (ROA) of 23.19 % in its first quarter of 2026, which is below Novo Nordisk A's average return on assets, which stands at 26.12%.

ROA has improved compared to 18.97% in the fourth quarter of 2025, due to net income growth.

However, within the Healthcare sector 51 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the fourth quarter of 2025 from to 216.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 1.07 % -76.33 % 35.54 % 43.37 % 97.24 %
Y / Y Net Income Change 85.56 % 5.49 % -22.09 % 39.24 % 10.81 %
Net Income (TTM) in million 19,025 15,518 15,296 16,184 15,049
Return On Assets (TTM) 23.19 % 18.97 % 10.16 % 11.14 % 10.78 %
NVO's Total Ranking # 216 # # # # 167
Total Assets (TTM) in million 86,217 85,308 80,537 76,065 85,308
Seq. Total Assets Change 1.07 % 5.92 % 5.88 % -10.84 % -76.33 %
Seq. Net Income Change 78.62 % 35.94 % -22.25 % -1.72 % 1.54 %

NVO's 5 Years Annual ROA >> Back to NVO Management Effectiveness >> Compare NVO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 21
Sector # 52
Overall # 265

Return On Assets Statistics
High Average Low
36.04 %
26.12 %
18.87 %
(Dec 31 2018)   (Dec 31 2025)





Financial Statements
Novo Nordisk A's Assets $ 86,217 million NVO's Balance sheet
Novo Nordisk A's Income $ 7,606 million Quarterly NVO's Income Statement
NVO's Income by Division See NVO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 16.55 % 898.1 % 34.47 % 17.24 % 24.28 %
Total Assets in million 542,902 465,795 46,668 34,706 29,604
Y / Y Net Income Change 1.43 % 731.29 % 54.53 % 3.48 % 17.78 %
Net Income in million 102,434 100,988 12,148 7,861 7,597
Annual Return On Assets 18.87 % 21.68 % 26.03 % 22.65 % 25.66 %

NVO's 5 Years Annual ROA >> Back to NVO Management Effectiveness >> Compare NVO ROA to its Competitors



Comment on NVO's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA deteriorated to 18.87 %, despite annual net income growth of 1.43 % to $102,434.00 million, from $100,988.00 million a year ago, as NVO's assets increase to $542,902.00 million, by 1.43 %.


More Return On Assets Ratios
NVO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NVO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NVO's Competitors
Subscribers only: Roa for Novo Nordisk A's Suppliers
Subscribers only: Return On Assets for NVO's Customers

You may also want to know
NVO's Roi NVO's Inventory Turnover Ratio NVO's Growth Rates NVO's Dividend Comparisons
NVO's Profitability Ratios NVO's Asset Turnover Ratio NVO's Dividend Growth
NVO's Roe NVO's Valuation Ratios NVO's Financial Strength Ratios NVO's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA
Advanced Biomed Inc.  60.23 %
Fortress Biotech Inc   58.36 %
Q32 Bio Inc   53.33 %
Coherus Oncology inc   50.33 %
Oramed Pharmaceuticals Inc  49.88 %
Aurinia Pharmaceuticals Inc   47.61 %
Zevra Therapeutics Inc   45.60 %
Earth Science Tech Inc   44.55 %
Tg Therapeutics Inc   42.77 %
Lensar Inc   42.26 %
Elite Pharmaceuticals Inc   38.74 %
Dariohealth Corp   37.08 %
Omeros Corporation  34.53 %
Idexx Laboratories Inc  32.56 %
Innoviva Inc   32.36 %
Agenus Inc  30.03 %
Abeona Therapeutics Inc   29.55 %
Escalon Medical Corp   29.20 %
Protagenic Therapeutics Inc new  27.96 %
Adma Biologics Inc   27.37 %
Rafael Holdings Inc  26.85 %
Acadia Pharmaceuticals Inc   26.24 %
Ironwood Pharmaceuticals inc   26.02 %
Theravance Biopharma inc   25.46 %
Spero Therapeutics Inc   24.95 %
Medpace Holdings Inc   24.79 %
Mettler toledo International Inc   24.47 %
Qhslab Inc   23.09 %
Eli Lilly And Company  22.73 %
Incyte Corporation  21.65 %

Date modified: 2026-09-23T16:04:42+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.